Carlsberg Spinout Traitomic Raises €20 Million to Speed Up Trait Development
Copenhagen-based biotech company Traitomic, spun out of brewer Carlsberg's research, has closed a €20 million Series A round. The money is meant to fund expansion in the US and Australia.

Traitomic, a company based in Copenhagen, Denmark, that grew out of research at Danish brewer Carlsberg, has raised €20 million (about $22 million) in a Series A investment round. It develops gene-screening technology for finding new traits in plants and microbes, and the fresh capital will let it expand internationally, starting with the US and Australia.
The round was led by investment firm Sofinnova Partners. Also taking part were EIFO, the Export and Investment Fund of Denmark, along with Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures.
How the technology works
Traitomic's FIND-IT platform was originally developed at the Carlsberg Research Laboratory. It identifies new traits without altering an organism's DNA. The platform looks for specific genetic variants in populations produced through conventional breeding — for example, a gene linked to sugar content in tomatoes. That variant then serves as starting material for a customer's own breeding programme or production strain.
Because the traits do not come from genetic engineering or gene editing, they can be sold as conventional products. This lets customers avoid regulatory hurdles that genetically modified organisms, and some gene-edited ones, face in many markets.
Potential uses are broad: changing the flavour or nutritional profile of foods, extending the shelf life of fresh produce, making crops more drought-tolerant, and improving enzymes and microbial strains used in industrial biotechnology.
Results and plans
Cofounder and CEO Gustav Hambraeus says many trait-development approaches are tied to a particular type of organism, such as crops, whereas Traitomic's is not. So far the company has delivered 116 traits to 47 customers across 32 organisms. Its clients work in plant breeding and seed, food supply chains and precision nutrition, and biosolutions and industrial biotech.
Traitomic has had a small presence in the US and Australia for the past couple of years and now plans to grow in both, including hiring locally. The funding will also allow it to take more risk alongside customers and move into new areas such as algae and mushrooms. Hambraeus says the key question over the next five or six years is whether these traits actually reach the market and are commercialised.


